75 related articles for article (PubMed ID: 19585750)
1. HDL-C as a new paradigm in atherosclerotic diseases.
Shilpha S; Bairy KL
Indian J Physiol Pharmacol; 2008; 52(4):319-26. PubMed ID: 19585750
[No Abstract] [Full Text] [Related]
2. Combating atherosclerosis with LXR alpha and PPAR alpha agonists: is rational multitargeted polypharmacy the future of therapeutics in complex diseases?
Kino T; Chrousos GP
Mol Interv; 2004 Oct; 4(5):254-7. PubMed ID: 15471908
[No Abstract] [Full Text] [Related]
3. New targets of high-density lipoprotein therapy.
Nicholls SJ; Nissen SE
Curr Opin Lipidol; 2007 Aug; 18(4):421-6. PubMed ID: 17620859
[TBL] [Abstract][Full Text] [Related]
4. Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo.
Guo L; Hu WR; Lian JH; Ji W; Deng T; Qian M; Gong BQ
Eur J Pharmacol; 2006 Dec; 551(1-3):80-6. PubMed ID: 17026988
[TBL] [Abstract][Full Text] [Related]
5. [New trends in lipidology: the increasing role of HDL-cholesterol].
Paragh G; Harangi M; László M
Orv Hetil; 2008 Jul; 149(30):1395-404. PubMed ID: 18621598
[TBL] [Abstract][Full Text] [Related]
6. [Advances in the study of anti-atherosclerosis drugs].
Guo CB; Li S
Yao Xue Xue Bao; 2007 Mar; 42(3):231-5. PubMed ID: 17520819
[TBL] [Abstract][Full Text] [Related]
7. Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist.
Mukherjee R; Locke KT; Miao B; Meyers D; Monshizadegan H; Zhang R; Search D; Grimm D; Flynn M; O'Malley KM; Zhang L; Li J; Shi Y; Kennedy LJ; Blanar M; Cheng PT; Tino J; Srivastava RA
J Pharmacol Exp Ther; 2008 Dec; 327(3):716-26. PubMed ID: 18799592
[TBL] [Abstract][Full Text] [Related]
8. The liver X receptor and atherosclerosis.
Scott J
N Engl J Med; 2007 Nov; 357(21):2195-7. PubMed ID: 18032771
[No Abstract] [Full Text] [Related]
9. HDL elevation and lipid lowering therapy: current scenario and future perspectives.
Chhabria MT; Suhagia BN; Brahmkshatriya PS
Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):214-27. PubMed ID: 18221121
[TBL] [Abstract][Full Text] [Related]
10. Liver X receptor activation and high-density lipoprotein biology: a reversal of fortune?
Lee CH; Plutzky J
Circulation; 2006 Jan; 113(1):5-8. PubMed ID: 16391165
[No Abstract] [Full Text] [Related]
11. Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis.
Hansen MK; Connolly TM
Curr Opin Investig Drugs; 2008 Mar; 9(3):247-55. PubMed ID: 18311660
[TBL] [Abstract][Full Text] [Related]
12. SAR studies: designing potent and selective LXR agonists.
Szewczyk JW; Huang S; Chin J; Tian J; Mitnaul L; Rosa RL; Peterson L; Sparrow CP; Adams AD
Bioorg Med Chem Lett; 2006 Jun; 16(11):3055-60. PubMed ID: 16529931
[TBL] [Abstract][Full Text] [Related]
13. Modulation of macrophage function and metabolism.
Bellosta S; Bernini F
Handb Exp Pharmacol; 2005; (170):665-95. PubMed ID: 16596819
[TBL] [Abstract][Full Text] [Related]
14. Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis.
Fiévet C; Staels B
Biochem Pharmacol; 2009 Apr; 77(8):1316-27. PubMed ID: 19101522
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapeutic strategies to enhance HDL function.
Redondo S; Martínez-González J; Urraca C; Tejerina T
Lipids Health Dis; 2011 Oct; 10():175. PubMed ID: 21985435
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Chapman MJ
Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
[TBL] [Abstract][Full Text] [Related]
17. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.
Tuteja S; Rader DJ
Clin Pharmacol Ther; 2014 Jul; 96(1):48-56. PubMed ID: 24713591
[TBL] [Abstract][Full Text] [Related]
18. The liver X receptors.
Lala DS
Curr Opin Investig Drugs; 2005 Sep; 6(9):934-43. PubMed ID: 16187693
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRalpha and beta.
Panday N; Benz J; Blum-Kaelin D; Bourgeaux V; Dehmlow H; Hartman P; Kuhn B; Ratni H; Warot X; Wright MB
Bioorg Med Chem Lett; 2006 Oct; 16(19):5231-7. PubMed ID: 16876993
[TBL] [Abstract][Full Text] [Related]
20. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men.
Rigamonti E; Chinetti-Gbaguidi G; Staels B
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1050-9. PubMed ID: 18323516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
